● Recruiting

Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma

Condition: Penile Carcinoma · Sponsor: H. Lee Moffitt Cancer Center and Research Institute

PhasePhase 2

Planned participants25

Who can joinMale, 18 Years to no upper limit

Healthy volunteersNo

About this study

The purpose of the study is to evaluate the efficacy and safety of the combination of niraparib and dostarlimab in patients participants with advanced relapsed/refractory penile cancer.

This description comes directly from the study's public registry record.

Talk to the study team

Contact details are listed per location below or on the registry record.

Always discuss trial participation with your own doctor first.

Locations (2)

Moffitt Cancer Center	Tampa, Florida, United States	Recruiting
MD Anderson Cancer Center	Houston, Texas, United States	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05526989